You are here

BeiGene

BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint

BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint

NJ Business

drug manufacturing

Flag link:

BeiGene pulls out of Leap of faith, letting option on immuno-oncology candidate lapse

BeiGene pulls out of Leap of faith, letting option on immuno-oncology candidate lapse

Fierce Biotech

immuno-oncology

Leap Therapeutics

Flag link:

Big Pharma regained ‘mojo’ last year, but biotech valuations remain ‘precarious’: report

Big Pharma regained ‘mojo’ last year, but biotech valuations remain ‘precarious’: report

Fierce Biotech

Moderna Therapeutics

Gilead Sciences

Flag link:

BeiGene doubles sales as Brukinsa, tislelizumab gear up for key launches

BeiGene doubles sales as Brukinsa, tislelizumab gear up for key launches

Fierce Pharma

Flag link:

This Week at FDA: Pallone pushes for greater ClinicalTrials.gov enforcement, FDA rejects Eli Lilly Alzheimer’s drug, and more

This Week at FDA: Pallone pushes for greater ClinicalTrials.gov enforcement, FDA rejects Eli Lilly Alzheimer’s drug, and more

RAPS.org

clinical trials

clinicaltrials.gov

Flag link:

BeiGene's Brukinsa wins CLL approval after topping Imbruvica in head-to-head trial

BeiGene's Brukinsa wins CLL approval after topping Imbruvica in head-to-head trial

Endpoints

Flag link:

Big caps bounce back for biopharma

Big caps bounce back for biopharma

EP Vantage

Bristol Myers Squibb

Gilead Sciences

Lantheus Holdings

Madrigal Pharmaceuticals

Moderna Therapeutics

Prometheus Biosciences

Flag link:

ASH 2022 – pirtobrutinib leads the post-Imbruvica charge

ASH 2022 – pirtobrutinib leads the post-Imbruvica charge

EP Vantage

Nurix Therapeutics

Flag link:

Go or no go? Mirati heads to the FDA

Go or no go? Mirati heads to the FDA

EP Vantage

Mirati Therapeutics

Gilead Sciences

Coherus Biosciences

TG Therapeutics

Flag link:

BeiGene heaps more pressure on AbbVie, J&J with new Brukinsa head-to-head win over Imbruvica

BeiGene heaps more pressure on AbbVie, J&J with new Brukinsa head-to-head win over Imbruvica

Fierce Pharma

Flag link:

ESMO 2022 – the new liver cancer entrants line up

ESMO 2022 – the new liver cancer entrants line up

EP Vantage

Flag link:

BeiGene and Novartis Make Late-Stage Progress against Liver Cancer

BeiGene and Novartis Make Late-Stage Progress against Liver Cancer

BioSpace

hepatocellular carcinoma

clinical trials

Flag link:

FDA Indefinitely Delays BeiGene/Novartis anti-PD-1 Esophageal Cancer Drug

FDA Indefinitely Delays BeiGene/Novartis anti-PD-1 Esophageal Cancer Drug

BioSpace

esophageal cancer

Flag link:

Doubling down on mRNA, BeiGene taps rising Hong Kong star to create targeted therapies

Doubling down on mRNA, BeiGene taps rising Hong Kong star to create targeted therapies

Fierce Biotech

Strand Therapeutics

Flag link:

Novartis, BeiGene lay out frontline PhIII data for PD-1 drug as second-line PDUFA date looms

Novartis, BeiGene lay out frontline PhIII data for PD-1 drug as second-line PDUFA date looms

Endpoints

gastrointestinal cancer

Flag link:

BeiGene Reports Lucrative Q1 Amid SEC Audit

BeiGene Reports Lucrative Q1 Amid SEC Audit

BioSpace

Flag link:

Novartis records another tislelizumab win en route to bringing BeiGene's PD-1 to FDA's doors

Novartis records another tislelizumab win en route to bringing BeiGene's PD-1 to FDA's doors

Endpoints

esophageal cancer

Flag link:

Outside of big pharma, life remains tough for listed developers

Outside of big pharma, life remains tough for listed developers

EP Vantage

Moderna Therapeutics

Flag link:

JPM22, Day 3: BeiGene, Ionis promise 'tidal wave' of new drugs; Roche launches smart, point-of-care glucose monitor

JPM22, Day 3: BeiGene, Ionis promise 'tidal wave' of new drugs; Roche launches smart, point-of-care glucose monitor

Fierce Biotech

Ionis Pharmaceuticals

Flag link:

Pages